FY2025 Earnings Estimate for OLMA Issued By Lifesci Capital

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) – Analysts at Lifesci Capital reduced their FY2025 earnings estimates for shares of Olema Pharmaceuticals in a research report issued to clients and investors on Monday, November 10th. Lifesci Capital analyst S. Slutsky now expects that the company will post earnings per share of ($1.86) for the year, down from their prior estimate of ($1.78). The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.33) per share. Lifesci Capital also issued estimates for Olema Pharmaceuticals’ Q4 2025 earnings at ($0.50) EPS.

Other equities research analysts have also recently issued reports about the company. JPMorgan Chase & Co. raised their price target on Olema Pharmaceuticals from $28.00 to $29.00 and gave the company an “overweight” rating in a report on Thursday, August 14th. Citigroup lifted their target price on Olema Pharmaceuticals from $20.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, August 12th. Zacks Research raised shares of Olema Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, September 9th. HC Wainwright reissued a “buy” rating and issued a $28.00 target price on shares of Olema Pharmaceuticals in a report on Monday, October 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research note on Wednesday, October 8th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Olema Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $23.00.

Olema Pharmaceuticals Stock Down 1.6%

OLMA opened at $8.06 on Thursday. The stock has a market cap of $553.19 million, a price-to-earnings ratio of -4.31 and a beta of 2.07. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.09 and a current ratio of 8.03. The firm’s fifty day moving average is $8.88 and its 200 day moving average is $6.27. Olema Pharmaceuticals has a fifty-two week low of $2.86 and a fifty-two week high of $12.70.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.05).

Hedge Funds Weigh In On Olema Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Candriam S.C.A. increased its holdings in shares of Olema Pharmaceuticals by 46.9% in the 3rd quarter. Candriam S.C.A. now owns 1,249,727 shares of the company’s stock worth $12,235,000 after buying an additional 399,273 shares during the last quarter. Campbell & CO Investment Adviser LLC purchased a new position in Olema Pharmaceuticals in the third quarter worth about $284,000. Thrivent Financial for Lutherans purchased a new position in shares of Olema Pharmaceuticals in the 2nd quarter worth approximately $308,000. Bridgeway Capital Management LLC bought a new position in shares of Olema Pharmaceuticals during the 2nd quarter valued at approximately $213,000. Finally, Birchview Capital LP purchased a new stake in Olema Pharmaceuticals during the 2nd quarter valued at $571,000. Institutional investors own 91.78% of the company’s stock.

Insider Buying and Selling at Olema Pharmaceuticals

In related news, Director Cyrus Harmon sold 10,000 shares of the business’s stock in a transaction on Thursday, September 18th. The shares were sold at an average price of $8.33, for a total value of $83,300.00. Following the sale, the director owned 744,140 shares in the company, valued at approximately $6,198,686.20. The trade was a 1.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold 25,000 shares of company stock valued at $204,841 over the last ninety days. Company insiders own 16.36% of the company’s stock.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.